All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 11 November 20263 min read

Skybiotech Healthcare (SKYBIOTECH) Q2 FY27's Loss Widens 158% as Subsidiary Costs Bite

The company's strategic pivot to pharmaceuticals is yet to generate revenue, while its subsidiary's costs pushed the consolidated loss to ₹0.8 crore in Q2 FY27.

By Abhinav Swaroop, CFA, Chief Business Officer: Hexawealth · Created 11 November 2026

Skybiotech Healthcare's consolidated net loss widened sharply to ₹0.8 crore in Q2 FY27, despite a sequential revenue jump. The loss was driven by elevated expenses at its subsidiary, while the standalone parent survives on investment income.

Skybiotech Healthcare's latest quarter underscores the growing pains of a company in transition. While the standalone entity managed a tiny profit from investments, its subsidiary's operational costs dragged the consolidated business deeper into the red, widening the loss by 158% from a year ago.

The numbers tell a story of two companies. Consolidated revenue of ₹1.04 crore was nearly half of last year's level, though it more than doubled from a dismal June quarter. The loss, however, ballooned to ₹0.8 crore.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 1.92, Q3 FY26 0.96, Q4 FY26 1.83, Q1 FY27 0.49, Q2 FY27 1.04. Q2 FY26 -0.31, Q3 FY26 -0.48, Q4 FY26 -0.3, Q1 FY27 -0.57, Q2 FY27 -0.8-4-2024Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 1.92
  • Revenue (₹ Cr), Q3 FY26: 0.96
  • Revenue (₹ Cr), Q4 FY26: 1.83
  • Revenue (₹ Cr), Q1 FY27: 0.49
  • Revenue (₹ Cr), Q2 FY27: 1.04
  • Profit (₹ Cr), Q2 FY26: -0.31
  • Profit (₹ Cr), Q3 FY26: -0.48
  • Profit (₹ Cr), Q4 FY26: -0.3
  • Profit (₹ Cr), Q1 FY27: -0.57
  • Profit (₹ Cr), Q2 FY27: -0.8

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 1.92, Q3 FY26 0.96, Q4 FY26 1.83, Q1 FY27 0.49, Q2 FY27 1.0401234Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26: 1.92
  • Revenue (₹ Cr), Q3 FY26: 0.96
  • Revenue (₹ Cr), Q4 FY26: 1.83
  • Revenue (₹ Cr), Q1 FY27: 0.49
  • Revenue (₹ Cr), Q2 FY27: 1.04

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 -0.31, Q3 FY26 -0.48, Q4 FY26 -0.3, Q1 FY27 -0.57, Q2 FY27 -0.8-2-1012Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Profit (₹ Cr), Q2 FY26: -0.31
  • Profit (₹ Cr), Q3 FY26: -0.48
  • Profit (₹ Cr), Q4 FY26: -0.3
  • Profit (₹ Cr), Q1 FY27: -0.57
  • Profit (₹ Cr), Q2 FY27: -0.8
MetricCurrentQ2 FY27PreviousQ1 FY27Same quarter LYQ2 FY26
Period
Sep 2026
Jun 2026
Sep 2025
Revenue (₹ Cr)
1.04YoY -46%
0.49
1.92
Profit (₹ Cr)
-0.8YoY -158%
-0.57
-0.31

The Standalone vs. Consolidated Split

A report from ScanX.trade highlights the core tension: the standalone parent reported zero revenue from operations. Its ₹2.31 lakh of other income, likely from investments, allowed a marginal profit of ₹1.76 lakh. All consolidated revenue and the bulk of expenses come from subsidiary Skybiotech Life Sciences.

This subsidiary is where the trouble lies. Its total expenses surged 70% quarter-on-quarter to ₹1.92 crore, far outpacing revenue growth. Employee costs rose, indicating fixed overheads remain high even as sales falter.

A Business in Transition

This performance comes amid a fundamental shift. The company, formerly Kapil Cotex, changed its name and business object last year to pharmaceuticals, as noted in its annual report. The rationale was clear: it generated no revenue from textiles.

Live Chart

· SKYBIOTECH

(BSE)

ISIN: INE393H01016

The new strategy is yet to bear fruit. The company is in the process of acquiring pharma registrations and licenses. Until that happens, it remains reliant on its subsidiary's unpredictable operations and the parent's investment income.

The Financial Strain

With a debt-to-equity ratio of 1.05 and a negative return on equity, the financial position is tight. A Simply Wall St analysis flagged that debt is not covered by operating cash flow as a major risk. The company has been funding itself through past preferential share issues.

The market's reaction has been muted, with the stock trading near 52-week lows. Flash Finance data shows sales for the quarter were 31.5% below the company's own historical trend.

Key Points

  • The consolidated net loss widened 158% year-on-year to ₹0.8 crore, driven by high expenses at the healthcare subsidiary.
  • Standalone operations generate no revenue, surviving on minor investment income, while all operational activity rests with the subsidiary.
  • The company is mid-pivot from textiles to pharmaceuticals, a transition that has yet to produce revenue from the new core business.
  • Financial metrics show strain, with high leverage and consistent cash burn from operations.

Hexa Perspective

The quarter reveals a holding company structure where the profitable part is inconsequential, and the operational part is loss-making. The 158% spike in the loss figure is dramatic, but the more telling trend is five straight quarters of consolidated losses.

The pivot to healthcare is a bet on the future, but the present is funded by balance sheet strength that is eroding. Investors are effectively waiting for the subsidiary to turn a corner or for the new pharma business to launch, with the clock ticking on cash reserves.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Skybiotech Healthcare (SKYBIOTECH) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Skybiotech Healthcare's Q2 FY27 results?
Skybiotech Healthcare reported a consolidated net loss of ₹0.8 crore for Q2 FY27 (September 2026 quarter), a 158% widening from the year-ago loss. Consolidated revenue was ₹1.04 crore, down 46% year-on-year but more than doubling from the previous quarter.
Why did Skybiotech Healthcare's Q2 FY27 loss widen 158%?
The loss widened primarily due to elevated operating expenses at its subsidiary, Skybiotech Life Sciences, as reported by ScanX.trade. Total consolidated expenses surged to ₹1.92 crore, significantly outpacing the ₹1.04 crore in revenue for the quarter.
What is the source of Skybiotech Healthcare's other income?
Skybiotech Healthcare's other income, which grew 112% year-on-year to ₹0.09 crore, comes from non-operational sources. ScanX.trade notes the standalone parent entity reported zero revenue from operations, with all income derived from other sources like investments.
What is the status of Skybiotech Healthcare's core business?
Skybiotech Healthcare's core business is in transition. According to its annual report, it has changed its object from manufacturing textiles to pharmaceuticals, as it generated no revenue from textiles. It is currently acquiring necessary pharma registrations and licenses.
How is Skybiotech Healthcare funding its operations given consistent losses?
Skybiotech Healthcare funds operations through its balance sheet and past capital raises. Simply Wall St analysis notes a risk as debt is not covered by operating cash flow. The company has raised capital via preferential share issues in recent years.
Did Skybiotech Healthcare's Q2 FY27 results beat analyst estimates?
There are no published analyst consensus estimates for comparison. However, data from Flash Finance indicates the company's Q2 sales of ₹1.04 crore were 31.5% below its own historical trend-based expectation.
How did Skybiotech Healthcare's stock price react to the Q2 results?
The stock was already trading near 52-week lows prior to the announcement. Specific price reaction data for November 14 is not available in the research, but the company has been under pressure, with MarketsMojo reporting it hit a fresh 52-week low in late October.
What guidance did Skybiotech Healthcare management provide?
The research snippets do not contain specific management guidance from an earnings call for Q2 FY27. The company's annual report states directors are optimistic about the future due to the planned entry into the new pharmaceuticals business line.
Is Skybiotech Healthcare planning any corporate restructuring?
Yes, the company has already undertaken a major restructuring. It changed its name from Kapil Cotex Limited and revised its main business object from textiles to manufacturing and trading of pharmaceutical products, as confirmed in its FY26 annual report.
What are the major risks highlighted for Skybiotech Healthcare?
Key risks include consistent operating losses, a high debt-to-equity ratio of 1.05, and negative cash flow from operations. Simply Wall St analysis flags that its debt is not covered by operating cash flow as a major financial risk.
Skybiotech Healthcare Q2 profit drop
Skybiotech Healthcare did not report a profit drop; it reported a loss. The consolidated net loss for Q2 FY27 was ₹0.8 crore, which was a 158% widening (increase) in loss compared to the ₹0.31 crore loss in Q2 FY26.
Skybiotech Healthcare Q2 net profit
Skybiotech Healthcare reported a consolidated net loss, not a profit, of ₹0.8 crore for Q2 FY27 (September 2026 quarter). The standalone parent entity reported a tiny net profit of ₹0.0176 crore, but this is not the consolidated figure.